Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis

Karl Winkler

Status: Completed

Conditions: Hypertension; Preeclampsia; Proteinuria; Dyslipidemia

Treatments: Other: lipid apheresis

Study type: Interventional

Funder types: Other

Identifiers

NCT01967355

2013-15

Details and patient eligibility

About

Preeclampsia is a disease which occurs in about 6-8% of all pregnancies and is the main cause of maternal and fetal morbidity and mortality. The cause of preeclampsia is still not clear and the only therapy is preterm caesarean section. In severe preeclampsia an accumulation of triglyceride-rich lipoproteins occurs. Therefore, lipid apheresis is performed as lipid-removing therapy for treatment of preeclampsia in order to prolong pregnancy and provide the fetus more time for maturation. In this individual treatment patients with early preeclampsia (<= 32 weeks of gestation) will be offered a H.E.L.P.-apheresis to postpone caesarean section and therefore prolong pregnancy.

Enrollment: 6 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pregnant women
• early preeclampsia (< 32 week of pregnancy)
• arterial hypertension during pregnancy
• proteinuria (=> 1 + dipstick or 0> 300 mg/24h)
• and/or intrauterine growth retardation (IUGR)
• informed consent

Exclusion criteria

• every acute indication for immediate delivery
• no informed consent

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

6 participants in 1 patient group

Lipid apheresis

Experimental group

Description:

Lipid apheresis: lipid removing therapy,frequency and duration depending on the symptoms of mother and fetus.

Treatment:

Other: lipid apheresis